Systemic Sclerosis: Clinical Trials

30 trials for Systemic Sclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

30 completed. 30 Phase 2, 5 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 230Completed 30
Phase 15Completed 5
Phase 32Completed 2

Follow Systemic Sclerosis: new trials by email Literature Review of Systemic Sclerosis trials Research Report on Systemic Sclerosis

Trials (filtered) newest first · largest first

All 30 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis
nemolizumab - Systemic Sclerosis
Phase 2CompletedMaruho Co., Ltd.62022-04-202026-02-13
A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis
GS-248, Placebo - Systemic Sclerosis
Phase 2CompletedGesynta Pharma AB942020-12-292024-08-09
Safety and Efficacy of Anaerobic Cultivated Human Intestinal Microbiome Transplantation in Systemic Sclerosis (ReSScue)
"ACHIM" as solute (10^9 intestinal microbes/ml) - Systemic Sclerosis
Phase 2CompletedOslo University Hospital752020-09-242022-10-12
Effects of Fractional CO2 Laser Treatment on Vaginal Symptoms and Sexual Dysfunction in Women With Systemic Sclerosis
CO2 Vaginal Laser - Systemic Sclerosis, Vulvovaginal Signs and Symptoms
Phase 2 / Phase 3CompletedIRCCS San Raffaele162020-05-012024-01-30
Cold Challenge With C21 in RP
C21, Placebo - Raynaud Phenomenon, Systemic Sclerosis
Phase 2CompletedVicore Pharma AB202020-01-032023-05-18
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis
GLPG1690, Placebo - Systemic Sclerosis
Phase 2CompletedLakefront Biotherapeutics NV332019-01-142021-05-04
Prednisolone in Early Diffuse Systemic Sclerosis
Prednisolone 5 mg, Placebo oral capsule; From August 2020 'no additional treatment' - Systemic Sclerosis
Phase 2CompletedProf. Ariane herrick352017-12-212021-07-30
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Tofacitinib, Placebo Oral Tablet - Systemic Sclerosis, Scleroderma
Phase 1 / Phase 2CompletedUniversity of Michigan152017-09-252020-05-08
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
SAR156597, Placebo - Systemic Sclerosis
Phase 2CompletedSanofi972016-12-212022-03-21
Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis
Oral treprostinil - Systemic Sclerosis, Calcinosis
Phase 2CompletedStanford University122016-10-012021-06-10
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
Bortezomib, Placebo, Mycophenolate mofetil - Lung Diseases, Interstitial, Systemic Sclerosis
Phase 2CompletedNorthwestern University92016-03-012021-08-25
Safety Of Fat Micrografts With Adipose-Derived Stromal Vascular Fraction In Hands Of Patients With Systemic Sclerosis
ADSVF application in the right hand - Systemic Sclerosis
Phase 2CompletedInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran202015-08-132020-05-15
Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)
Ambrisentan, Placebo - Systemic Sclerosis, Pulmonary Hypertension
Phase 2CompletedHeidelberg University382014-07-012020-04-30
Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
Interleukin 2 - Rheumatoid Arthritis, Ankylosing Spondylitis
Phase 2CompletedAssistance Publique - Hôpitaux de Paris812014-01-062021-07-20
Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)
Pirfenidone - Systemic Sclerosis
Phase 2CompletedGenentech, Inc.632013-10-012016-08-04
Rituximab in Systemic Sclerosis
Rituximab, Placebo (NaCl) - Systemic Sclerosis
Phase 2 / Phase 3CompletedAssistance Publique - Hôpitaux de Paris222013-04-092025-11-20
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
SAR100842, Placebo (for SAR100842) - Systemic Sclerosis
Phase 2CompletedSanofi322013-01-012016-03-25
Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Belimumab, Mycophenolate Mofetil, Placebo Infusion - Systemic Sclerosis
Phase 2CompletedHospital for Special Surgery, New York202012-08-012022-05-24
An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod)
paquinimod - Systemic Sclerosis
Phase 2CompletedActive Biotech AB92011-12-012014-08-27
IL1-TRAP, Rilonacept, in Systemic Sclerosis
Rilonacept, Placebo - Scleroderma, Systemic Sclerosis
Phase 1 / Phase 2CompletedBoston University242011-12-012018-05-01

Showing 20 of 30. Sign in to see all of them.

Narrower conditions

Scleroderma, Systemic (30)  ·  Scleroderma, Diffuse (12)  ·  Arthritis (3)  ·  Connective Tissue Diseases (2)  ·  Lung Diseases, Interstitial (2)  ·  Pain (2)  ·  Rare Diseases (2)  ·  Raynaud Disease (2)  ·  Aortic Arch Syndromes (1)  ·  Arthritis, Rheumatoid (1)  ·  Behcet Syndrome (1)  ·  Calcinosis (1)  ·  Cholangitis, Sclerosing (1)  ·  Colitis, Ulcerative (1)  ·  Crohn Disease (1)

Broader conditions

Skin Diseases (30)  ·  Skin and Connective Tissue Diseases (30)  ·  Connective Tissue Diseases (28)  ·  Pathological Conditions, Signs and Symptoms (7)  ·  Lung Diseases (5)  ·  Pathologic Processes (5)  ·  Respiratory Tract Diseases (5)  ·  Cardiovascular Diseases (4)  ·  Joint Diseases (4)  ·  Musculoskeletal Diseases (4)  ·  Vascular Diseases (4)  ·  Signs and Symptoms (3)  ·  Skin Diseases, Vascular (3)  ·  Disease Attributes (2)  ·  Embolism and Thrombosis (2)

Interventions

Imatinib Mesylate (2)  ·  Mycophenolic Acid (2)  ·  treprostinil (2)  ·  Antilymphocyte Serum (1)  ·  Bortezomib (1)  ·  Cognitive Behavioral Therapy (1)  ·  Cyclophosphamide (1)  ·  Fecal Microbiota Transplantation (1)  ·  GLPG1690 (1)  ·  Interleukin-2 (1)  ·  Methotrexate (1)  ·  Prednisolone (1)  ·  Relaxin (1)  ·  Rituximab (1)  ·  SAR-100842 (1)

Sponsors

Hospital for Special Surgery, New York (3)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  Sanofi (2)  ·  University of California, Los Angeles (2)  ·  Active Biotech AB (1)  ·  Boston University (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Genentech, Inc. (1)  ·  Genzyme, a Sanofi Company (1)  ·  Gesynta Pharma AB (1)  ·  Heidelberg University (1)  ·  IRCCS San Raffaele (1)  ·  Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1)  ·  Johns Hopkins University (1)  ·  Lakefront Biotherapeutics NV (1)

Countries

United States (18)  ·  United Kingdom (7)  ·  Italy (5)  ·  France (4)  ·  Germany (4)  ·  Belgium (3)  ·  Canada (2)  ·  Mexico (2)  ·  Poland (2)  ·  Switzerland (2)  ·  Argentina (1)  ·  Estonia (1)  ·  Japan (1)  ·  Netherlands (1)  ·  Norway (1)

Top investigators

Robert Spiera, MD (3)  ·  Anna-Maria Hoffmann-Vold, MD, PhD (1)  ·  Ariane Herrick, MD (1)  ·  Ayumi Yoshizaki, MD, PhD (1)  ·  Carlos Hinojosa, MD (1)  ·  Charlotte Edenius (1)  ·  Daniel E. Furst, MD (1)  ·  Dinesh Khanna, MD (1)  ·  G. Scott Herron (1)  ·  James Seibold, MD (1)

Results publications

PMID 28298564, PMID 19950289, PMID 21398330, PMID 21769849, PMID 26283632, PMID 27370878, PMID 29073351, PMID 29732731, PMID 30277862, PMID 30472651, PMID 31655622, PMID 31858338, PMID 32963047, PMID 34168032, PMID 34330322, PMID 34718447, PMID 35894657, PMID 35943798, PMID 36637209, PMID 39900089

NIH funding

2019 (2), 2016 (1), 2018 (1), R01AR047219 (1), R34HL122558 (1)